Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: BT-001

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001

Published 25 May 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Invir.IO, Press release

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Published 14 November 2022
Categorized as 2022, BT-001, dates, Press release

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®

Transgene and bioinvent announce clinical collaboration

Published 28 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Transgene and BioInvent announce positive progress for BT-001

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 27 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF

JB Marchand et al. AACR 2022 Abstract available on the AACR website – Download the poster

Published 11 April 2022
Categorized as 2022, BT-001, Publication

Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022

Transgene and BioInvent Announce Poster Presentation on BT-001

Published 9 March 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Press release

Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade

Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade

Published 20 January 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Press release

Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

20211109 – Transgene BioInvent SITC BT-001 en

Published 9 November 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021

BT-001 oncolytic virus at SITC 2021

Published 1 October 2021
Categorized as 2021, BT-001, Press release

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Published 1 July 2021
Categorized as -others, -others, 2021, BT-001, Publication, TG6002

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu